TOP 20 cited articles in Pharmacology, Toxicology and Pharmaceutics(2006—2010)

作者:发布时间:2010/5/5 10:04:29

1. Free radicals, metals and antioxidants in oxidative stress-induced cancer
Valko, M. (2006), Chemico-Biological Interactions, Volume 160, Issue 1, Pages 1-40 Cited by: 546

2. Anticancer activities of histone deacetylase inhibitors
Bolden, J.E. (2006), Nature Reviews Drug Discovery, Volume 5, Issue 9, Pages 769-784 Cited by: 473

3. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Dominici, M. (2006), Cytotherapy, Volume 8, Issue 4, Pages 315-317 Cited by: 471

4. Natural products as sources of new drugs over the last 25 years
Newman, D.J. (2007), Journal of Natural Products, Volume 70, Issue 3, Pages 461-477 Cited by: 409

5. Therapeutic potential of resveratrol: The in vivo evidence
Baur, J.A. (2006), Nature Reviews Drug Discovery, Volume 5, Issue 6, Pages 493-506 Cited by: 405

6. The 2005 World Health Organization reevaluation of human and mammalian toxic equivalency factors for dioxins and dioxin-like compounds
Van den Berg, M. (2006), Toxicological Sciences, Volume 93, Issue 2, Pages 223-241 Cited by: 361

7. Angiogenesis: An organizing principle for drug discovery?
Folkman, J. (2007), Nature Reviews Drug Discovery, Volume 6, Issue 4, Pages 273-286 Cited by: 359

8. Guide to Receptors and Channels (GRAC), 3rd edition
Alexander, S.P.H. (2008), British Journal of Pharmacology, Volume 153, Issue SUPPL. 2, Pages S1-S196 Cited by: 346

9. The endocannabinoid system as an emerging target of pharmacotherapy
Pacher, P. (2006), Pharmacological Reviews, Volume 58, Issue 3, Pages 389-462 Cited by: 337

10. Targeting multidrug resistance in cancer
Szakács, G. (2006), Nature Reviews Drug Discovery, Volume 5, Issue 3, Pages 219-234 Cited by: 315

11. Molecular targets of dietary agents for prevention and therapy of cancer
Aggarwal, B.B. (2006), Biochemical Pharmacology, Volume 71, Issue 10, Pages 1397-1421 Cited by: 298

12. Therapeutic potential of toll-like receptor 9 activation
Krieg, A.M. (2006), Nature Reviews Drug Discovery, Volume 5, Issue 6, Pages 471-484 Cited by: 294

13. Epigenetic therapy of cancer: Past, present and future
Yoo, C.B. (2006), Nature Reviews Drug Discovery, Volume 5, Issue 1, Pages 37-50 Cited by: 288

14. Adenosine receptors as therapeutic targets
Jacobson, K.A. (2006), Nature Reviews Drug Discovery, Volume 5, Issue 3, Pages 247-264 Cited by: 263

15. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
Bender, A.T. (2006), Pharmacological Reviews, Volume 58, Issue 3, Pages 488-520 Cited by: 226

16. How many drug targets are there?
Overington, J.P. (2006), Nature Reviews Drug Discovery, Volume 5, Issue 12, Pages 993-996 Cited by: 224

17. Lab-on-a-chip: Microfluidics in drug discovery
Dittrich, P.S. (2006), Nature Reviews Drug Discovery, Volume 5, Issue 3, Pages 210-218 Cited by: 224

18. Organocatalytic asymmetric conjugate additions
Almaşi, D. (2007), Tetrahedron Asymmetry, Volume 18, Issue 3, Pages 299-365 Cited by: 220

19. Transition metal catalyzed oxidative functionalization of carbon-hydrogen bonds
Dick, A.R. (2006), Tetrahedron, Volume 62, Issue 11, Pages 2439-2463 Cited by: 212

20. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
Owens III, D.E. (2006), International Journal of Pharmaceutics, Volume 307, Issue 1, Pages 93-102 Cited by: 211

稿件来源:SCOPUS